PLACTM test for identification of individuals at increased risk for coronary heart disease

被引：20

作者：

Hoogeveen, RC ^{[1
]}

Ballantyne, CM ^{[1
]}

机构：

[1] Baylor Coll Med, Sect Atherosclerosis & Lipoprot Res, Dept Med,Methodist DeBakey Heart Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX 77030 USA

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2005年 / 5卷 / 01期

关键词：

cardiovascular disease; inflammatory markere; lipoprotein-associated; phospholipase A2; auboxidative stress; PLAC(TM); test;

D O I：

10.1586/14737159.5.1.9

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Recent advances In cardiovascular research point to a critical role of inflammatory processes In the etiology of cardiovascular disease. This has led to the discovery of novel Inflammatory blomarkers, which may be useful as additional screening tools for the Identification of Individuals at Increased risk of coronary heart disease. One such novel inflammatory biomarker Is lipoprotein-associated phospholipase A(2). This review discusses the recent development of a US Food and Drug Administration-approved blood test for lipoprotein-associated phospholipase A(2) (PLAC (TM) test, diaDexus, Inc.) and Its efficacy as a predictive biomarker of risk for cardiovascular disease. More specifically, the article addresses the potential target group most likely to benefit from this new screening test and provides a prospective scenario for Its Implementation.

引用

页码：9 / 14

页数：6

共 52 条

[1] Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe [J].